Hepatic lymphoma is a lymphoproliferative neoplasm seen in the liver as primary or secondary. Primary hepatic lymphoma is extremely rare (<1% of all extranodal lymphomas) — mostly diffuse large B-cell lymphoma (DLBCL) type. Secondary liver involvement is common; liver involvement is detected in up to 50% of advanced Hodgkin and Non-Hodgkin lymphoma. Imaging characteristically shows homogeneous hypodense lesions, marked DWI restriction, and high FDG uptake. Primary hepatic lymphoma risk increases in immunosuppressed patients (HIV, transplant).
Age Range
40-80
Peak Age
60
Gender
Male predominant
Prevalence
Uncommon
Primary hepatic lymphoma originates from resident lymphoid cells in the liver such as Kupffer cells or portal tract lymphocytes. Immunosuppression (HIV, organ transplant) and chronic liver diseases like hepatitis C are risk factors — chronic antigenic stimulation triggers lymphoid proliferation. EBV-associated post-transplant lymphoproliferative disease (PTLD) is an important subgroup. Lymphoma cells show dense cellularity but do not form significant neoangiogenesis — lesions are therefore hypovascular. High cellularity forms the basis for DWI restriction and FDG uptake. In secondary involvement, hematogenous or lymphatic spread of systemic lymphoma occurs.
The combination of a homogeneous hypodense/hypointense liver lesion with marked DWI restriction and high FDG uptake is the signature triad of hepatic lymphoma. This combination indicates a hypovascular but metabolically highly active tumor — highly characteristic of lymphoma. HCC (hypervascular), metastasis (heterogeneous), and abscess (clinical context) are distinguished by this triad.
Homogeneous hypodense lesion(s) on non-contrast CT. Necrosis, hemorrhage, and calcification are typically absent — reflecting the homogeneous cellular structure of lymphoma. May present as a solitary large mass or multiple lesions.
Report Sentence
Homogeneous hypodense lesion(s) are seen in the liver without necrosis or calcification.
Minimal or mild enhancement in portal venous phase — lesion remains markedly hypodense. Enhancement is low due to hypovascular character. Some cases may show mild homogeneous enhancement.
Report Sentence
The lesions demonstrate minimal enhancement on contrast-enhanced series, consistent with hypovascular character.
Marked diffusion restriction on DWI — bright signal on high b-value images. Low ADC values on ADC maps (typically <0.8 × 10⁻³ mm²/s). The most sensitive MRI finding of lymphoma.
Report Sentence
The lesions demonstrate marked diffusion restriction on DWI sequences with low ADC values.
High FDG uptake on PET-CT (SUVmax usually >10-15). FDG avidity plays a critical role in diagnosis, staging, and treatment response evaluation in lymphoma. DLBCL and Hodgkin lymphoma show the highest FDG uptake.
Report Sentence
High FDG uptake (SUVmax: ___) is seen in the liver lesions on PET-CT, consistent with lymphoma.
Mild to moderate hyperintensity on T2. Homogeneous signal structure — no necrosis/hemorrhage areas. Lower signal than the marked T2 hyperintensity of hemangioma and cysts.
Report Sentence
The lesions show mild to moderate homogeneous hyperintensity on T2-weighted sequences.
Hypointense signal on T1 — markedly dark relative to liver parenchyma. Minimal or mild enhancement on contrast-enhanced series.
Report Sentence
The lesions demonstrate hypointense signal on T1-weighted sequences.
Criteria
Most common primary hepatic lymphoma type (50-60%). Solitary large mass or multiple lesions. Associated with immunosuppression/hepatitis C.
Distinct Features
Aggressive course but good response to chemotherapy (R-CHOP). Homogeneous large mass + minimal mass effect. Hepatic parenchymal invasion is infiltrative.
Criteria
Liver involvement of systemic lymphoma. Common in advanced Hodgkin/NHL (30-50%). Multiple small lesions or diffuse infiltration.
Distinct Features
Known systemic lymphoma history — not isolated liver involvement. Usually accompanied by splenomegaly and widespread lymphadenopathy. Whole-body staging is performed with PET-CT.
Criteria
Develops in the setting of immunosuppression after organ transplant. EBV-associated (60-80%). Early PTLD (first year) polyclonal, late PTLD monoclonal/aggressive.
Distinct Features
Transplant history is the critical clue. Reduction of immunosuppression is the first treatment step. Graft involvement may occur in liver transplant recipients.
Distinguishing Feature
HCC is hypervascular and shows intense arterial enhancement — lymphoma is hypovascular with minimal enhancement. HCC develops in cirrhotic liver, lymphoma usually in non-cirrhotic liver. HCC is heterogeneous while lymphoma is homogeneous.
Distinguishing Feature
ICC shows peripheral enhancement and progressive delayed filling — lymphoma shows minimal enhancement. Biliary dilatation and capsular retraction are common in ICC — these findings are not expected in lymphoma. ICC typically has desmoplastic stroma.
Distinguishing Feature
Abscess also shows DWI restriction but rim enhancement, double target sign, and peripheral edema are typical — lymphoma shows minimal/homogeneous enhancement. Clinical context (fever, leukocytosis) is prominent in abscess. Abscess responds to treatment with size reduction.
Distinguishing Feature
Epithelioid hemangioendothelioma shows peripheral distribution, target sign (T2) and lollipop sign — lymphoma does not show these distinct patterns. Capsular retraction is common in EHE. EHE typically presents as multiple peripheral nodules.
Urgency
urgentManagement
medicalBiopsy
NeededFollow-up
3-monthBiopsy is required for diagnosis in hepatic lymphoma — histological type determination guides treatment planning (DLBCL vs follicular vs Hodgkin). Core biopsy (percutaneous) is preferred. Treatment is chemotherapy: R-CHOP for DLBCL (rituximab + CHOP), ABVD for Hodgkin. Reduction of immunosuppression is the first step in PTLD. Primary hepatic lymphoma generally responds well to chemotherapy — 50-60% complete remission achievable. Treatment response should be evaluated with PET-CT using Deauville criteria at 3-month intervals. The role of surgical resection is limited.
Hepatic lymphoma is treated with chemotherapy; the role of surgery is limited. Primary hepatic lymphoma is rare and has a better prognosis than systemic lymphoma. Histopathological diagnosis via biopsy is required.